Skip to main content

Table 1 Baseline characteristics of the PROSPER/PHASE study

From: Replication of LDL GWAs hits in PROSPER/PHASE as validation for future (pharmaco)genetic analyses

 

PROSPER study (n = 5804)

PROSPER/PHASE study (n = 5244)

Continuous variables (mean, SD)

  

   Age (years)

75.3 (3.3)

75.3 (3.4)

   Education (years)

15.1 (2.0)

15.1 (2.0)

   Systolic blood pressure (mmHg)

154.7 (21.8)

154.6 (21.9)

   Diastolic blood pressure (mmHg)

83.8 (11.5)

83.7 (11.4)

   Height (cm)

165.2 (9.4)

165.2 (9.4)

   Weight (kg)

73.4 (13.4)

73.3 (13.4)

   Body mass index (kg/m2)

26.8 (4.2)

26.8 (4.2)

   Total cholesterol (mmol/L)

5.7 (0.9)

5.7 (0.9)

   LDL cholesterol (mmol/L)

3.8 (0.8)

3.8 (0.8)

   HDL cholesterol (mmol/L)

1.3 (0.3)

1.3 (0.4)

   Triglycerides (mmol/L)

1.5 (0.7)

1.5 (0.7)

Categorical variables (n, %)

  

   Males

2804 (48.3)

2524 (48.1)

   Current smoker

1558 (26.8)

1392 (26.5)

   History of diabetes

623 (10.7)

544 (10.4)

   History of hypertension

3592 (61.9)

3257 (62.1)

   History of angina

1559 (26.9)

1424 (27.2)

   History of claudication

390 (6.7)

354 (6.8)

   History of myocardial infarction

776 (13.4)

708 (13.5)

   History of stroke or TIA

649 (11.2)

586 (11.2)

   History of vascular disease*

2565 (44.2)

2336 (44.5)

  1. *Any of stable angina, intermittent claudication, stroke, transient ischemic attack, myocardial infarction, peripheral artery disease surgery, or amputation for vascular disease more than 6 months before study entry.